Recurrent Solid Tumors
7
1
1
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
28.6%
2 terminated out of 7 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
ONO-4538 Phase I Study in Patients With Solid Tumor
ONO-4538 Phase I Study in Patients With Solid Tumor
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors